Skip to main content
. Author manuscript; available in PMC: 2012 Oct 3.
Published in final edited form as: Mol Pharm. 2011 Jul 29;8(5):1720–1728. doi: 10.1021/mp200080h

Figure 4. The binding peptide and the selectivity of targeting.

Figure 4

(A) MCF-7-specific phage-liposomes containing binding peptide (DMPGTVLP) fused to the N-terminus of phage PVIII coat protein, showing specific binding to MCF-7 cells co-cultured with C166-GFP cells; (B) Control streptavidin-specific phage-liposomes containing binding peptide (VPEGAFSS) fused to N-terminus of phage pVIII coat protein, showing a non-preferential binding to co-cultured MCF-7 cells and C166-GFP cells. (C) Streptavidin-specific phage-liposomes showing significantly higher binding to streptavidin coated on a microplate than MCF-7-specific phage-liposomes (mean ± SD, n=8). Brocade bar: Streptavidin-specific phage-liposomes; Grey Bar: MCF-7-specific phage-liposomes.

HHS Vulnerability Disclosure